Selected research from leading health care experts whose findings have a direct bearing on public policies effecting medical progress. Research is chosen based on its quality and relevance by the Medical Progress Today editorial staff.

Selected Research

Fluoxetine, Cognitive-Behavioral Therapy, and Their Combination for Adolescents With Depression
The Journal of the American Medical Association, 8-18-04

This study compared the relative effectiveness of fluoxetine (Prozac), cognitive-behavioral therapy, and placebo in adolescent patients with a diagnosis of major depressive disorder. The trial found that combination therapy (Prozac plus CBT) had the best response rate (71%) compared to Prozac alone (60%), CBT alone (43%) and placebo (35%). One interesting note given the recent hue and cry over a potential link between suicidal tendencies among adolescents and anti-depressant use: "Clinically significant suicidal thinking, which was present in 29% of the sample at baseline, improved significantly in all 4 treatment groups."

Project FDA.
home   spotlight   commentary   research   events   news   about   contact   links   archives
Copyright Manhattan Institute for Policy Research
52 Vanderbilt Avenue
New York, NY 10017
(212) 599-7000